Stay updated on AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial
Sign up to get notified when there's something new on the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page.

Latest updates to the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page
- CheckyesterdayChange DetectedRevision: v3.3.4 was added and v3.3.3 was removed.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded a Locations section listing study sites (California, Illinois, Maryland) and updated the page to revision v3.3.3. The HHS Vulnerability Disclosure link was removed.SummaryDifference0.4%

- Check44 days agoChange DetectedThe page revision indicator was updated from v3.3.1 to v3.3.2.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page shows a minor version revision from v3.2.0 to v3.3.1, with no changes to study content, eligibility criteria, or listed locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check58 days agoChange DetectedRemoved the government funding lapse notice; no core study content or eligibility information was changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check73 days agoChange DetectedMinimal changes detected: only minor layout/UI updates with no impact on core study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page.